The retrospective study involved nearly 2.8 million male veterans 65 to 99 years of age, 32.3% with diabetes, who received primary care at Veterans Health Administration medical centers from 2000 to 2010.
The American Heart Association (AHA) addressed use of antithrombotics, hypertension drugs, and cholesterol therapies in patients with stable coronary artery disease and diabetes, among other recommendations.
Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds
The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.
health status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
Risk for major adverse cardiovascular events and all-cause mortality was higher when a sulfonylurea was added to metformin compared to other typical second- or third-line therapy options in a recent Danish study.
Screening tool identifies high-risk drivers with type 1 diabetes and website helps to avoid future accidents
Significant independent predictors of risk for driving mishaps included annual driving distance and presence of peripheral neuropathy. Researchers developed an 11-item questionnaire to further refine risk prediction.
Compared to those with type 1 diabetes, participants with type 2 had a significantly higher age-adjusted prevalence of diabetic kidney disease, retinopathy, peripheral, arterial stiffness, and hypertension by age 21.
Dapagliflozin associated with lower risk for all-cause mortality in type 2 diabetes regardless of CVD risk, study finds
The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
Mean HbA1c was 5.7% in the African-American participants with sickle cell trait and 6.0% in those without, despite similar mean fasting and two-hour glucose values.